Alireza Eghtedar, MD
Hematology & Oncology · Denver, CONPI 1811280431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,388 of the $96,151 with a category attached, or 73.2%. 32 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 59.3% of the total. Reporting peaked in 2019 at $91,199 and has fallen 99.2% since, to $753 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $435.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$57K
- Bristol Myers Squibb$15K
- Novartis$12K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Verastem, Inc.$3K
- AbbVie$386
- plus $2K from 26 others
Across 166 payments — averaging $2975.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$153K
- Takeda Pharmaceuticals U.S.A., Inc.$152K
- Sumitomo Pharma America, Inc.$102K
- Novartis$84K
- National Marrow Donor Program$4K
What the payments were for
- Consulting fees$4,5005%
- Speaking & faculty fees$70,38873%
- Travel & lodging$15,12816%
- Food & beverage$5,9706%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 75 | $57,037 |
| Bristol Myers Squibb | 28 | $15,141 |
| Novartis | 22 | $11,657 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $7,209 |
| Verastem, Inc. | 2 | $2,765 |
| AbbVie | 17 | $386 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $312 |
| Johnson & Johnson | 7 | $240 |
| Pfizer | 4 | $181 |
| E.r. Squibb & Sons, L.L.C. | 2 | $170 |
| Astellas Pharma US Inc | 5 | $107 |
| Incyte Corporation | 5 | $90 |
| Genentech USA, Inc. | 4 | $81 |
| Sumitomo Pharma America, Inc. | 1 | $73 |
| Blueprint Medicines Corporation | 3 | $72 |
| Amgen | 3 | $66 |
| Merck | 4 | $65 |
| Rigel Pharmaceuticals, Inc. | 1 | $63 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Beigene USA, Inc. | 2 | $52 |
| Gilead | 1 | $49 |
| Genmab U.S., Inc. | 2 | $49 |
| GSK | 2 | $38 |
| Agios Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Invivyd Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,151 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 84 | $1,320,208 |
| CalquenceAcalabrutinib Maleate | 29 | $431,570 |
| PomalystPomalidomide | 13 | $342,396 |
| RezurockBelumosudil Mesylate | 14 | $295,104 |
| XospataGilteritinib Fumarate | 14 | $293,225 |
| CresembaIsavuconazonium Sulfate | 19 | $116,807 |
| PrevymisLetermovir | 16 | $113,996 |
| VenclextaVenetoclax | 13 | $76,186 |
| Posaconazole | 25 | $42,647 |
| EliquisApixaban | 31 | $34,013 |
| ValacyclovirValacyclovir Hcl | 161 | $7,897 |
| Sirolimus | 48 | $3,934 |
| Fluconazole | 27 | $2,478 |
| Acyclovir | 100 | $1,754 |
| Ursodiol | 11 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $90 | $1,320,20884 claims |
| Astellas Pharma US IncXospata, Cresemba | $107 | $410,03233 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $170 | $342,39613 claims |
| Sanofi-aventis U.S. LLCRezurock | $23 | $295,10414 claims |
| MerckPrevymis | $65 | $113,99616 claims |
| AbbVieVenclexta | $386 | $76,18613 claims |
| PfizerEliquis | $181 | $34,01331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
- Marcello RottaDenver$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.